Results 1 to 10 of about 128,118 (293)

A case of chronic myelogenous leukemia in pregnancy characterized by a complex translocation t(9;22;11)(q34;q11.2;q13) [PDF]

Hematology Reports, 2011
The management of chronic myelogenous leukemia during pregnancy requires balancing the well-being of the mother with that of the fetus. We report a case of a 26-year-old lady who was diagnosed with chronic myelogenous leukemia (CML) at 15 weeks gestation
Surachit Kumar, Mariya Apostolova, Paul V. Woolley   +2 more
doaj   +2 more sources

Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis

Haematologica, 2013
Second generation tyrosine kinase inhibitors have recently been introduced as first-line treatment for chronic phase chronic myelogenous leukemia. We aimed to evaluate the efficacy and safety of 2nd generation tyrosine kinase inhibitors versus imatinib ...
Ronit Gurion, Anat Gafter-Gvili, Liat Vidal, Avi Leader, Ron Ram, Adi Shacham-Abulafia, Mical Paul, Isaac Ben-Bassat, Ofer Shpilberg, Pia Raanani   +9 more
doaj   +3 more sources

Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy

Frontiers in Cardiovascular Medicine, 2022
BackgroundPulmonary hypertension (PH) is a rare but life-threatening adverse event (AE) of dasatinib, but the associated variables are not clear. This study aimed to explore the variables associated with PH by echocardiography in patients with chronic ...
Wenying Jin, Sen Yang, Chao Yu, Tiangang Zhu, Qian Jiang, Qian Jiang   +5 more
doaj   +1 more source

Chronic Myelogenous Leukemia [PDF]

Journal of the National Comprehensive Cancer Network, 2012
Chronic myelogenous leukemia (CML) is the one of the most common chronic myeloproliferative disorders. It has become the paradigmatic disease for molecular diagnosis and monitoring for several reasons: (1) CML has a unitary molecular definition, requiring the demonstration of the t(9;22)(q34;q11) chromosomal translocation or its product, the BCR-ABL ...
Susan, O'Brien, Camille N, Abboud, Mojtaba, Akhtari, Jessica, Altman, Ellin, Berman, Daniel J, DeAngelo, Steven, Devine, Amir T, Fathi, Jason, Gotlib, Madan, Jagasia, Joseph O, Moore, Javier, Pinilla-Ibarz, Jerald P, Radich, Vishnu V B, Reddy, Neil P, Shah, Paul J, Shami, B Douglas, Smith, David S, Snyder, Meir, Wetzler, Furhan, Yunus   +19 more
openaire   +2 more sources

Priapism as the first manifestation in chronic myeloid leukemia: A case report and focused review of literature

Clinical Case Reports, 2021
We report the case of a patient who was initially presented with ischemic priapism to the emergency department. He was treated with adrenaline intracavernous injections and aspiration with irrigation of the corpora cavernosa and distal shunt.
Claudia Lucia Sossa Melo, Carlos Alberto Orozco Orozco, Angela Maria Peña Castellanos, Maria Alejandra Rueda Perea, Cristian Orlando Porras Bueno, Carlos Ivan Romero Diaz, Helga Natalia Rojas Rodríguez   +6 more
doaj   +1 more source

Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells

Biomolecular Concepts, 2021
The BCR-ABL oncogene is a tyrosine kinase gene that is over-expressed in CML. It inhibits the TGF-β1 signaling pathway. Due to resistance of cells to the tyrosine kinase inhibitor, STI-571, the combined effect of STI-571 and TGF-β1 on K562 cells was ...
Bakhshayesh Masoome, Gohari Ladan Hosseini, Barati Mahmood, Safa Majid   +3 more
doaj   +1 more source

Granulocytic Sarcoma with Compressive Myelopathy: A Rare Presentation of Chronic Myelogenous Leukemia [PDF]

Journal of Clinical and Diagnostic Research, 2014
Granulocytic sarcoma occurs most commonly in acute myelogenous leukemia. The appearance of granulocytic sarcoma in chronic myelogenous leukemia signals accelerated phase/ blast transformation.
Abhijeet P. Ganapule, Auro Viswabandya, Anita Jasper, Palak Patel, Gautami Kokil   +4 more
doaj   +1 more source

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance

Revista Brasileira de Hematologia e Hemoterapia, 2013
OBJECTIVE: The goal of this study was to monitor imatinib mesylate therapeutically in the Tumor Biology Laboratory, Department of Hematology and Hemotherapy, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP).
Vinícius Marcondes Rezende, Ariane Julio Rivellis, Melissa Medrano Gomes, Felipe Augusto Dörr, Mafalda Megumi Yoshinaga Novaes, Luciana Nardinelli, Ariel Lais de Lima Costa, Dalton de Alencar Fisher Chamone, Israel Bendit   +8 more
doaj   +3 more sources

Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient. [PDF]

Int J Hematol
Oka S, Akagi Y, Mituyoshi T, Ono K.
europepmc   +3 more sources

Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients

Revista Brasileira de Hematologia e Hemoterapia, 2015
Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or t(9;22)(q34.1;q11.2), resulting in the break-point cluster regionAbelson tyrosine kinase fusion gene, which encodes a constitutively ...
Maria de Lourdes Lopes Ferrari Chauffaille, Ana Carolina de Almeida Bandeira, Aline Schiavoni Guarnieri da Silva   +2 more
doaj   +1 more source